Drug delivery device with a needle cover lock

Abstract

The application provides a drug warehouse-out analysis supervision method and system based on an Internet of Things device, and belongs to the technical field of supervision, and specifically comprises the following steps: when the verification processing delay of a verification processing strategy does not meet the requirements, the update result of the verification processing strategy of the drug and other drugs in the Internet of Things device is determined based on the concerned physical index data and the warehouse-out data of the drug and other drugs when the drug and other drugs are used jointly; and the verification target of the drug in the patients with different inspection data in the Internet of Things device is determined based on the verification processing strategy of the drug and other drugs in the Internet of Things device, so that the reliability of the identification processing of the joint use contraindication is improved.

Description

Technical Field

[0001] This invention belongs to the field of regulatory technology, and in particular relates to a method and system for drug outbound analysis and supervision based on Internet of Things (IoT) devices. Background Technology

[0002] There may be some contraindications during the combined preparation of drugs, such as causing liver damage, rashes, allergies, etc. Therefore, it is necessary to use Internet of Things (IoT) devices to monitor and analyze the drugs during the combined preparation process, so as to promptly identify contraindications for combined use. A similar technical solution is given in the invention patent application CN202510918895.5 "A Terminal Data Management Method and System for Pharmaceutical Sales".

[0003] However, in actual configuration, when facing different patients, there may be patients with abnormal indicators when the drug is used in combination with other drugs. Therefore, how to use the data of patients with abnormal indicators to determine the identification scheme of contraindications for the combined use of the drug with other drugs, so as to improve the efficiency and reliability of the identification and processing of contraindications for the combined use of the drug with other drugs, has become an urgent technical problem to be solved.

[0004] To address the aforementioned technical issues, this application provides a method and system for analyzing and monitoring drug delivery based on Internet of Things (IoT) devices. Summary of the Invention

[0005] To achieve the objectives of this invention, the following technical solution is adopted:

[0006] Specifically, this application provides a method for drug outbound analysis and supervision based on Internet of Things (IoT) devices, which includes:

[0007] S1 uses IoT scanning devices as a basis to determine the combined configuration data of the drug and other drugs, and uses the combined configuration data as a basis to identify patients with abnormal indicators during the combined configuration process of the drug, and uses the data of patients with abnormal indicators to determine the verification and processing strategy of IoT devices for the contraindication of combined use of the drug.

[0008] S2 When the verification processing delay of the verification processing strategy does not meet the requirements, the updated result of the verification processing strategy of the drug and other drugs in the Internet of Things device is determined based on the health indicators data and outbound data when the drug is used in combination with other drugs.

[0009] S3, based on the verification processing strategy of the drug and other drugs in IoT devices, determines the verification targets of the drug in IoT devices for patients with different examination data.

[0010] The beneficial effects of this invention are as follows:

[0011] By using data from patients with abnormal indicators, a verification and processing strategy for IoT devices to determine contraindications for combined drug use was developed. This strategy enables the determination of contraindications for combined drug use from the perspective of patients with abnormal indicators, ensuring the reliability and efficiency of identifying and processing contraindications for combined use of drugs for a large number of patients with abnormal indicators.

[0012] Based on the verification and processing strategy of drugs and other drugs in IoT devices, the verification targets of drugs in patients with different examination data are determined in IoT devices. This avoids the technical problem of poor identification reliability caused by a large number of other drugs when using fixed contraindication features for the analysis and processing of contraindications of drugs used in combination. By performing secondary verification processing on patients with a large number of examination items, the reliability of the verification and processing is further improved. At the same time, it also ensures the reliable updating of fixed contraindication features that have not been updated in a timely manner. That is, when new contraindications for combined use are found, the fixed contraindication features are updated in a timely manner.

[0013] Furthermore, the combined configuration data of the drug with other drugs includes data on the simultaneous use of the drug and other drugs in different patients.

[0014] Furthermore, the patients with abnormal indicators during the combined preparation of the drug are those whose physical indicators do not meet the contraindications for combined use when the drug is used in combination with other drugs.

[0015] Furthermore, the method for determining the verification and processing strategy for IoT devices that are contraindicated in the combined use of the aforementioned drugs is as follows:

[0016] Based on the data of patients with abnormal indicators, identify patients with abnormal indicators when the drug is used in combination with other drugs;

[0017] Based on other drug data of patients with abnormal indicators, determine the verification and processing strategy for IoT devices that indicate contraindications to the combined use of the drugs.

[0018] Furthermore, when the number of patients with abnormal indicators during the combined use of the drug with other drugs meets the requirements, the combined use of the drug with other drugs for patients with abnormal indicators will be checked for contraindications in both the IoT scanning device and the monitoring device. In other cases, the combined use contraindications will only be checked in the IoT scanning device.

[0019] Furthermore, the method for determining the verification target of the drug in patients with different examination data using IoT devices is as follows:

[0020] Based on the verification and processing strategy of the drug and other drugs in IoT devices, other drugs that only need to be checked for contraindications of joint use in IoT barcode scanning devices are identified and identified as drugs with analytical deviations.

[0021] Based on the analysis deviation drug and the joint outbound data of the drug, the number of joint outbound transactions of the drug and the analysis deviation drug is determined;

[0022] By utilizing the combined outbound frequency and analyzing the deviation drug data, the verification targets of the drug on IoT devices are determined for patients with different examination data.

[0023] Secondly, the present invention provides a computer system comprising: a memory and a processor connected in communication, and a computer program stored in the memory and capable of running on the processor, wherein the processor executes the aforementioned method for analyzing and monitoring drug delivery based on an Internet of Things (IoT) device when running the computer program.

[0024] Other features and advantages will be set forth in the following description, and the objects and other advantages of the invention are realized and obtained through the structures particularly pointed out in the description and the drawings.

[0025] To make the above-mentioned objects, features and advantages of the present invention more apparent and understandable, preferred embodiments are described below in detail with reference to the accompanying drawings. Attached Figure Description

[0026] The above and other features and advantages of the present invention will become more apparent from a detailed description of exemplary embodiments thereof with reference to the accompanying drawings.

[0027] Figure 1 This is a flowchart of a drug outbound analysis and supervision method based on Internet of Things (IoT) devices;

[0028] Figure 2 This is a flowchart illustrating the method for determining the verification and processing strategy of IoT devices for contraindications to the combined use of drugs;

[0029] Figure 3 This is a flowchart for determining whether the verification processing delay of the verification processing strategy does not meet the requirements;

[0030] Figure 4 This is a flowchart illustrating the method for determining the update results of the verification and processing strategy for pharmaceuticals and other pharmaceuticals in Internet of Things (IoT) devices.

[0031] Figure 5 It is a framework diagram of a computer system. Detailed Implementation

[0032] To enable those skilled in the art to better understand the technical solutions in this specification, the technical solutions in the embodiments of this specification will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of this specification, and not all embodiments. Based on the embodiments of this specification, all other embodiments obtained by those skilled in the art without creative effort should fall within the scope of protection of this specification.

[0033] In this application, for some drugs used in combination, verification is performed using an IoT barcode scanning device. Specifically, the IoT barcode scanning device outputs the scanning results to a computer system. The computer system uses fixed contraindications for combined use to verify the drugs and other drugs. For some drugs used in combination, verification is also performed using a monitoring device. Specifically, the monitoring device determines the drugs to be released based on monitoring images of the actual drugs released and other drugs. The released drugs, patient medical records, and examination data are used as input to a large model. Based on the output of the large model, it determines whether there are any contraindications. The large model is called through an API interface, thereby avoiding the impact of computer analysis lag on drug release efficiency and achieving seamless contraindication verification.

[0034] Example 1

[0035] like Figure 1 As shown, this application provides a method for drug outbound analysis and supervision based on Internet of Things (IoT) devices, specifically including:

[0036] S1 uses IoT scanning devices as a basis to determine the combined configuration data of the drug and other drugs, and uses the combined configuration data as a basis to identify patients with abnormal indicators during the combined configuration process of the drug, and uses the data of patients with abnormal indicators to determine the verification and processing strategy of IoT devices for the contraindication of combined use of the drug.

[0037] Specifically, the IoT scanning device is a device for scanning the QR codes of medicines.

[0038] Furthermore, the combined configuration data of the drug with other drugs includes data on the simultaneous use of the drug and other drugs in different patients.

[0039] Specifically, patients with abnormal indicators during the combined preparation of the drug are those whose physical indicators do not meet the contraindications for combined use when the drug is used in combination with other drugs.

[0040] For example, when using nephrotoxic drugs in combination (such as aminoglycosides + ACEIs), the contraindications include: serum creatinine > 265 μmol / L. When using ACEIs / ARBs in combination with potassium-sparing diuretics / penicillin, the contraindications include: serum potassium > 5.5 mmol / L, serum creatinine increase > 30%, systolic blood pressure < 90 mmHg, glomerular filtration rate < 60 ml / min / 1.73 m², and urine output < 400 ml / day. If there are physical indicators that do not meet the contraindications for combined use, the patient is identified as a patient with abnormal indicators.

[0041] It should be noted that the IoT devices include monitoring devices and IoT barcode scanning devices. To improve the efficiency of drug dispensing, verification is performed in the IoT barcode scanning devices. Specifically, the IoT barcode scanning devices output the scanning results to the computer system. The computer system uses fixed contraindications for combined use to verify the drug and other drugs. Verification is also performed in the monitoring devices. Specifically, the monitoring devices determine the dispensing drugs based on monitoring images of the actual dispensing drugs and other drugs. The dispensing drugs, patient medical records, and examination data are used as input to a large model. Based on the output of the large model, it is determined whether there are any contraindications. The large model is called through an API interface, realizing seamless contraindication verification.

[0042] Specifically, such as Figure 2 As shown, the method for determining the verification and processing strategy for IoT devices that are contraindicated in the combined use of the aforementioned drugs is as follows:

[0043] Based on the data of patients with abnormal indicators, identify patients with abnormal indicators when the drug is used in combination with other drugs;

[0044] Other medications for patients with abnormal indicators are considered high-risk medications. Based on data on the combined use of these high-risk medications and other medications, a verification and processing strategy for IoT devices is determined to identify contraindications for the combined use of these medications.

[0045] In one possible embodiment, when the data on the combined use of the risky drug and the drug does not meet the requirements, i.e. when the outbound volume is large, the verification and processing strategy for determining the contraindication of combined use of the drug by the Internet of Things (IoT) device is to perform the verification and processing of the contraindication of combined use in both the IoT barcode scanning device and the monitoring device.

[0046] In one possible embodiment, if the number of patients using the risky drug in combination with the drug accounts for more than 0.6% of the total number of patients using the drug, then the data on the combined use of the risky drug and the drug is determined to be unsatisfactory.

[0047] It should also be noted that when the data on the combined use of the risky drug and the drug meets the requirements, the combined use of the drug with other drugs for patients with abnormal indicators will be checked for contraindications in both the IoT scanning device and the monitoring device. In other cases, only the IoT scanning device needs to be checked for contraindications.

[0048] S2 When the verification processing delay of the verification processing strategy does not meet the requirements, the updated result of the verification processing strategy of the drug and other drugs in the Internet of Things device is determined based on the health indicators data and joint outbound data when the drug is used in combination with other drugs.

[0049] Specifically, such as Figure 3 As shown, determining that the verification processing delay of the verification processing strategy does not meet the requirements specifically includes:

[0050] Based on the historical data of verification and analysis, determine the number of times that the analysis of contraindications for combined use has not been completed in the monitoring device after the drugs and combined drugs have been released from the warehouse, and use this number as the number of delayed verifications;

[0051] Based on the number of delayed verifications across different drugs, drugs with delayed verification processing were identified.

[0052] The verification processing delay of the aforementioned verification processing strategy is determined based on the drug data with verification processing delays and the number of delayed verifications on different dates.

[0053] It is understood that the drugs with delayed verification processing are those that have had a history of delayed verification.

[0054] Furthermore, if the average number of delayed verifications on different dates does not meet the requirements, then it is determined that the verification processing delay of the verification processing strategy does not meet the requirements.

[0055] Additionally, it can be understood that when the average number of delayed verifications on different dates meets the requirements, if the average number of delayed verifications on different dates is not within the preset range, then the number of delayed verifications is low, and the verification processing delay of the verification processing strategy is determined to meet the requirements.

[0056] Furthermore, if the average number of delayed verifications on different dates is within a preset range, then if the number of drugs with delayed verification processing does not meet the requirements, it is determined that the verification processing delay of the verification processing strategy does not meet the requirements; otherwise, it is determined that the verification processing delay of the verification processing strategy meets the requirements.

[0057] In one possible embodiment, if the average number of delayed verifications across different dates is between 5 and 10, then the average number of delayed verifications across different dates is determined to be within a preset range. Conversely, if the average number of delayed verifications across different dates is greater than 10, then the average number of delayed verifications across different dates is determined to be unsatisfactory. Specifically, if the number of drugs with delayed verification processing is not less than 5, then the number of drugs with delayed verification processing is determined to be unsatisfactory.

[0058] Furthermore, such as Figure 4 As shown, the method for determining the update result of the verification processing strategy for the drug and other drugs in the Internet of Things device is as follows:

[0059] Based on the contraindication data of the drug in combination with other drugs, determine the physical indicators that need to be paid attention to when the drug is used in combination with other drugs, and use them as related physical indicators;

[0060] Based on the joint outbound data, determine the number of times the drug and other drugs were jointly outbound on different dates, and determine the percentage of the number of times the other drugs were jointly outbound based on the number of joint outbounds.

[0061] Based on the proportion of joint outbound shipments of different drugs and related physical indicators, the updated results of the verification and processing strategies for drugs and other drugs in IoT devices are determined.

[0062] Specifically, when the proportion of the number of times the drug is jointly shipped out with other drugs is less than the preset proportion threshold, it indicates that the distribution of the drug being jointly shipped out with other drugs is relatively discrete. Therefore, based on this, it is determined that the verification and processing strategy for the drug and other drugs in the Internet of Things (IoT) device still only requires verification and processing of the prohibition of joint use in the IoT barcode scanning device.

[0063] Furthermore, when the proportion of the number of times different other drugs are jointly shipped out is not less than the preset proportion threshold, the number of related physical indicators of the other drugs is determined. When the number of related physical indicators of the other drugs meets the requirements, the verification and processing strategy of the drug and other drugs in the Internet of Things device is determined to be that the verification and processing of the contraindication of joint use only needs to be carried out in the Internet of Things scanning device.

[0064] Additionally, it should be noted that when the number of associated health indicators of the other drugs does not meet the requirements, it is also necessary to determine the ratio of the number of associated health indicators of the other drugs to the number of joint outbound shipments. If both the number of associated health indicators of the other drugs and the ratio of the number of joint outbound shipments are within a preset range, then the verification and processing strategy for the drugs and other drugs in the IoT device is determined to be that the verification and processing of the contraindications for joint use only needs to be performed in the IoT barcode scanning device. In other cases, the verification and processing of the contraindications for joint use is determined to be performed in both the IoT barcode scanning device and the monitoring device.

[0065] Furthermore, the contraindications for combined use are determined based on the analysis results of the drug's instructions for use.

[0066] S3, based on the verification processing strategy of the drug and other drugs in IoT devices, determines the verification targets of the drug in IoT devices for patients with different examination data.

[0067] It should be noted that the patient's examination data includes the number of examination items and the results of those items. Specific examination items include blood pressure, pulse, complete blood count, blood biochemistry tests including liver function (transaminase, bilirubin), kidney function (creatinine, urea nitrogen), blood glucose, blood lipids (cholesterol, triglycerides), urinalysis: detecting urine protein, urine glucose, white blood cells, etc., to diagnose kidney disease or urinary tract infection, ultrasound: examining the morphology of organs such as the liver, gallbladder, pancreas, spleen, and kidneys, X-ray / CT / MRI: assessing structural abnormalities such as fractures and tumors, electrocardiogram: recording cardiac electrical activity, diagnosing diseases such as arrhythmia, liver function: detecting indicators such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), assessing liver function, and kidney function: detecting indicators such as creatinine and urea nitrogen, reflecting kidney filtration function.

[0068] Specifically, the method for determining the verification target of the drug in patients with different examination data using IoT devices is as follows:

[0069] Based on the verification and processing strategy of the drug and other drugs in IoT devices, other drugs that only need to be checked for contraindications of joint use in IoT barcode scanning devices are identified and identified as drugs with analytical deviations.

[0070] Based on the analysis deviation drug and the joint outbound data of the drug, the number of joint outbound transactions of the drug and the analysis deviation drug is determined;

[0071] By utilizing the combined outbound frequency and analyzing the deviation drug data, the verification targets of the drug on IoT devices are determined for patients with different examination data.

[0072] It should be noted that when the analytical deviation drug does not meet the requirements, since there is a deviation in the contraindication of the combined use of the drug, a second verification of the contraindication of combined use is performed on the monitoring device, based on the fact that the examination data of the patient using the combined drug and the analytical deviation drug meet the requirements.

[0073] In one possible embodiment, if the proportion of the analytically biased drug in other drugs used in combination with the drug is greater than 0.4, then the analytically biased drug is determined to be unacceptable. In this case, if the number of examination items for patients using the drug in combination with the analytically biased drug is not less than 3, then the examination data for patients using the drug in combination with the analytically biased drug is determined to be acceptable.

[0074] Additionally, it should be noted that when the analytical deviation drug meets the requirements, it is necessary to further determine the number of times the drug and the analytical deviation drug are jointly issued. When the average daily number of times the drug and the analytical deviation drug are jointly issued does not meet the requirements, the amount of analytical deviation drug issued is relatively large. Therefore, based on the fact that the examination data of patients using the drug and the analytical deviation drug in combination meet the requirements, a secondary verification of the contraindications for combined use is performed in the monitoring device.

[0075] In one possible embodiment, if the average daily number of joint shipments of the drug and the analytically biased drug is more than 20, then it is determined that the average daily number of joint shipments of the drug and the analytically biased drug does not meet the requirements.

[0076] Furthermore, when the average daily number of joint outbound shipments of the drug and the analytical deviation drug meets the requirements, if the drug has joint outbound shipment data with the analytical deviation drug on different dates, then the examination data of patients using the drug in combination with the analytical deviation drug meets the requirements, i.e., a secondary verification process for contraindications of joint use is performed in the monitoring device. However, if the drug does not have joint outbound shipment data with the analytical deviation drug on different dates, then if the number of times the analytical deviation drug undergoes secondary verification process for contraindications of joint use in the monitoring device on the current date is less than a preset threshold, then the examination data of patients using the drug in combination with the analytical deviation drug meets the requirements, i.e., a secondary verification process for contraindications of joint use is performed in the monitoring device.

[0077] Example 2

[0078] Secondly, such as Figure 5As shown, the present invention provides a computer system, including: a memory and a processor connected in communication, and a computer program stored in the memory and capable of running on the processor. When the processor runs the computer program, it executes the above-described method for drug outbound analysis and supervision based on Internet of Things (IoT) devices.

[0079] Optionally, the method for determining the verification target of the drug in patients with different examination data using IoT devices is as follows:

[0080] Based on the verification and processing strategy of the drug and other drugs in IoT devices, other drugs that only need to be checked for contraindications of joint use in IoT barcode scanning devices are identified and identified as drugs with analytical deviations.

[0081] Based on the analysis deviation drug and the joint outbound data of the drug, the number of joint outbound transactions of the drug and the analysis deviation drug is determined;

[0082] Using the combined outbound frequency, the verification targets of the drug on IoT devices are determined among patients with different examination data.

[0083] Optionally, if the drug has joint release data with the analytically biased drug on different dates, then, based on the fact that the examination data of patients using the drug in combination with the analytically biased drug meets the requirements, a secondary verification process for the contraindication of joint use is performed in the monitoring device. However, if the drug does not have joint release data with the analytically biased drug on different dates, then, if the number of times the analytically biased drug undergoes secondary verification of the contraindication of joint use in the monitoring device on the current date is less than a preset threshold, then, based on the fact that the examination data of patients using the drug in combination with the analytically biased drug meets the requirements, a secondary verification process for the contraindication of joint use is performed in the monitoring device.

[0084] In one possible embodiment, if the number of times the analysis deviation drug is subjected to secondary verification of contraindications for combined use in the monitoring device is less than 30 times on the current date, then the secondary verification of contraindications for combined use in the monitoring device is performed based on the fact that the examination data of the patient using the drug in combination with the analysis deviation drug meets the requirements.

[0085] Example 3

[0086] Specifically, the method for determining the update result of the verification and processing strategy for the aforementioned drug and other drugs in the Internet of Things device is as follows:

[0087] Based on the contraindication data of the drug in combination with other drugs, determine the physical indicators that need to be paid attention to when the drug is used in combination with other drugs, and use them as related physical indicators;

[0088] Based on the joint outbound data, determine the number of times the drug was jointly outbound with other drugs on different dates;

[0089] Based on the associated physical indicators and the number of times drugs were jointly shipped out with other drugs on different dates, the updated results of the verification and processing strategy for drugs and other drugs in IoT devices were determined.

[0090] It should be noted that the number of times the drug is jointly shipped with other drugs on different dates is determined. If the average number of times the drug is jointly shipped with other drugs on different dates meets the requirements, it indicates that the number of times the drug is shipped with other drugs is relatively small. Based on this, there is no need to update the verification and processing strategy for all other drugs that are used in combination with the drug, and the original verification and processing strategy will still be used.

[0091] In one possible embodiment, if the average number of times the drug and other drugs are jointly shipped out on different dates is less than 30, then the average number of times the drug and other drugs are jointly shipped out on different dates is determined to meet the requirement.

[0092] It is understandable that if the average number of times the drug and other drugs are jointly shipped out on different dates does not meet the requirements, then when the drug and other drugs only need to undergo joint use prohibition verification processing in the IoT scanning device, it is determined that the verification processing strategy for the drug and other drugs in the IoT device still belongs to the category of only needing joint use prohibition verification processing in the IoT scanning device.

[0093] Furthermore, when the drug and other drugs only require verification of contraindications for combined use in IoT scanning devices, then the verification strategy for the drug and other drugs in IoT devices is determined to still require verification of contraindications for combined use in IoT scanning devices.

[0094] Furthermore, it is understood that when the drug and other drugs do not fall under the category of requiring only joint use prohibition verification processing in IoT barcode scanning devices, the proportion of the number of times the drug is jointly shipped with different other drugs to the total number of times the drug is jointly shipped with other drugs is obtained, and this proportion is used as the proportion of the number of times other drugs are jointly shipped. When the proportion of the number of times different other drugs are jointly shipped is less than a preset proportion threshold, it indicates that the distribution of the drug's joint shipment with different other drugs is relatively dispersed. Therefore, based on this, it is determined that the verification processing strategy for the drug and other drugs in IoT devices still falls under the category of requiring only joint use prohibition verification processing in IoT barcode scanning devices.

[0095] In one possible embodiment, when the proportion of the number of times different other drugs are jointly shipped out is less than 0.1, it is determined that the proportion of the number of times different other drugs are jointly shipped out is less than a preset proportion threshold.

[0096] Furthermore, when the proportion of the number of times different other drugs are jointly shipped out is not less than the preset proportion threshold, the number of related physical indicators of the other drugs is determined. When the number of related physical indicators of the other drugs meets the requirements, that is, there is only 1, the verification and processing strategy of the drug and other drugs in the Internet of Things device is determined to be that the verification and processing of the contraindication of joint use only needs to be carried out in the Internet of Things scanning device.

[0097] Additionally, it should be noted that when the number of associated health indicators of the other drugs does not meet the requirements, it is also necessary to determine the ratio of the number of associated health indicators of the other drugs to the number of joint outbound shipments. If both the number of associated health indicators of the other drugs and the ratio of the number of joint outbound shipments are within a preset range, then the verification and processing strategy for the drugs and other drugs in the IoT device is determined to be that the verification and processing of the contraindications for joint use only needs to be performed in the IoT barcode scanning device. In other cases, the verification and processing of the contraindications for joint use is determined to be performed in both the IoT barcode scanning device and the monitoring device.

[0098] In one possible embodiment, if the number of associated physical indicators of the other drugs is less than two and the proportion of joint outbound shipments is between 0.1 and 0.2, then the verification and processing strategy for the drugs and other drugs in the IoT device is determined to be that joint use contraindication verification is only required in the IoT barcode scanning device.

[0099] Example 4

[0100] Specifically, the method for determining the verification and processing strategy for IoT devices that are contraindicated in the combined use of the aforementioned drugs is as follows:

[0101] Based on the data of patients with abnormal indicators, identify patients with abnormal indicators when the drug is used in combination with other drugs;

[0102] Based on other drug data of patients with abnormal indicators, determine the verification and processing strategy for IoT devices that indicate contraindications to the combined use of the drugs.

[0103] It is understandable that when the drug is used in combination with other drugs, and there are patients with abnormal indicators in different other drugs, the verification and processing strategy for IoT devices that determine the contraindication of the combined use of the drug is to perform the verification and processing of the contraindication of combined use in both IoT scanning devices and monitoring devices.

[0104] Furthermore, it is understood that when the drug is used in combination with other drugs, and there are not uniformly abnormal indicators among the other drugs, the number of patients with abnormal indicators during the combined use of the drug with other drugs is obtained. If the number of patients with abnormal indicators during the combined use of the drug with other drugs does not meet the requirements, the verification and processing strategy for IoT devices that determine the contraindication of combined use of the drug is to perform the verification and processing of the contraindication of combined use in both IoT scanning devices and monitoring devices.

[0105] In one possible embodiment, if the number of patients with abnormal indicators during the combined use of the drug and other drugs is greater than 0.2 compared to the proportion of patients using the drug in combination with other drugs, then it is determined that the number of patients with abnormal indicators during the combined use of the drug and other drugs does not meet the requirement.

[0106] Furthermore, when the number of patients with abnormal indicators during the combined use of the drug with other drugs meets the requirements, the combined use of the drug with other drugs for patients with abnormal indicators will be checked for contraindications in both the IoT scanning device and the monitoring device. In other cases, the combined use contraindications will only be checked in the IoT scanning device.

[0107] The various embodiments in this specification are described in a progressive manner. Similar or identical parts between embodiments can be referred to mutually. Each embodiment focuses on describing the differences from other embodiments. In particular, the embodiments of apparatus, devices, and non-volatile computer storage media are basically similar to the method embodiments, so the descriptions are relatively simple; relevant parts can be referred to the descriptions of the method embodiments.

[0108] The foregoing has described specific embodiments of this specification. Other embodiments are within the scope of the appended claims. In some cases, the actions or steps recited in the claims may be performed in a different order than that shown in the embodiments and may still achieve the desired result. Furthermore, the processes depicted in the drawings do not necessarily require the specific or sequential order shown to achieve the desired result. In some embodiments, multitasking and parallel processing are possible or may be advantageous.

[0109] The above description is merely one or more embodiments of this specification and is not intended to limit this specification. Various modifications and variations can be made to the one or more embodiments of this specification by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principle of one or more embodiments of this specification should be included within the scope of the claims of this specification.

Claims

1. A method for analyzing and monitoring drug outbound shipments based on Internet of Things (IoT) devices, characterized in that, Specifically, it includes: Based on IoT scanning devices, the combined configuration data of drugs with other drugs is determined, and the combined configuration data is used to identify patients with abnormal indicators during the combined configuration process of the drugs. Based on the data of patients with abnormal indicators, the verification and processing strategy of IoT devices for the contraindication of combined use of the drugs is determined. When the verification processing delay of the verification processing strategy does not meet the requirements, the updated result of the verification processing strategy for the drug and other drugs in the Internet of Things device is determined based on the health indicators data and outbound data when the drug is used in combination with other drugs. Based on the verification and processing strategy of the drug and other drugs in IoT devices, the verification targets of the drug in IoT devices are determined in patients with different examination data. Determining that the verification processing delay of the aforementioned verification processing strategy does not meet the requirements specifically includes: Based on the historical data of verification and analysis, determine the number of times that the analysis of contraindications for combined use has not been completed in the monitoring device after the drugs and combined drugs have been released from the warehouse, and use this number as the number of delayed verifications; Based on the number of delayed verifications across different drugs, drugs with delayed verification processing were identified. Based on the drug data with verification processing delays and the number of delayed verifications on different dates, determine whether the verification processing delay of the verification processing strategy meets the requirements; The method for determining the verification target of the drug in patients with different examination data using IoT devices is as follows: Based on the verification and processing strategy of the drug and other drugs in IoT devices, other drugs that only need to be checked for contraindications of joint use in IoT barcode scanning devices are identified and identified as drugs with analytical deviations. Based on the analysis deviation drug and the joint outbound data of the drug, the number of joint outbound transactions of the drug and the analysis deviation drug is determined; By utilizing the combined outbound frequency and analyzing the deviation drug data, the verification targets of the IoT device for the drug are determined among patients with different examination data.

2. The drug outbound analysis and supervision method based on IoT devices as described in claim 1, characterized in that, The IoT scanning device is a device for scanning the QR codes of medicines.

3. The drug outbound analysis and supervision method based on IoT devices as described in claim 1, characterized in that, The combined configuration data of the drug with other drugs includes data on the simultaneous use of the drug and other drugs in different patients.

4. The drug outbound analysis and supervision method based on IoT devices as described in claim 1, characterized in that, Patients with abnormal indicators during the combined preparation of the drug are those whose physical indicators do not meet the contraindications for combined use of the drug with other drugs.

5. The drug outbound analysis and supervision method based on IoT devices as described in claim 1, characterized in that, The method for determining the verification and processing strategy for IoT devices that are contraindicated in the combined use of the aforementioned drugs is as follows: Based on the data of patients with abnormal indicators, identify patients with abnormal indicators when the drug is used in combination with other drugs; Based on other drug data of patients with abnormal indicators, determine the verification and processing strategy for IoT devices that indicate contraindications to the combined use of the drugs.

6. The drug outbound analysis and supervision method based on IoT devices as described in claim 5, characterized in that, When the drug is used in combination with other drugs, and there are patients with abnormal indicators in different other drugs, the verification and processing strategy for IoT devices that determine the contraindication of the combined use of the drug is to perform the verification and processing of the contraindication of combined use in both IoT scanning devices and monitoring devices.

7. The drug outbound analysis and supervision method based on IoT devices as described in claim 1, characterized in that, The method for determining the update result of the verification and processing strategy for the aforementioned drug and other drugs in the Internet of Things device is as follows: Based on the contraindication data of the drug in combination with other drugs, determine the physical indicators that need to be paid attention to when the drug is used in combination with other drugs, and use them as related physical indicators; Based on the joint outbound data, determine the number of times the drug was jointly outbound with other drugs on different dates; Based on the associated physical indicators and the number of times drugs were jointly shipped out with other drugs on different dates, the updated results of the verification and processing strategy for drugs and other drugs in IoT devices were determined.

8. The drug outbound analysis and supervision method based on Internet of Things (IoT) devices as described in claim 1, characterized in that, When the drug and other drugs only require verification of contraindications for combined use in IoT scanning devices, there is no need to update the verification strategy for all other drugs that are used in combination with the drug; the original verification strategy will still be used.

9. A computer system, comprising: A memory and processor connected by communication, and a computer program stored in the memory and capable of running on the processor, characterized in that, when the processor runs the computer program, it executes a drug outbound analysis and supervision method based on any one of claims 1-8.

Images